Sign in
Taking peopleNo phase

Effectiveness of Chatbot for Improving Caregiving Outcomes in Primary Caregivers of Geriatric Pneumonia Patients: A Study on Knowledge, Attitude and Practice.

Key facts

Who runs it
Taipei Veterans General Hospital, Taiwan
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
150 people, planned
Started
13 Mar 2026
Expected to end
24 Feb 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Chatbot with Educational Videos
  • Traditional Paper-based Education
Record updated
14 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients with a primary diagnosis of pneumonia during the current hospitalization
  • Patients aged 65 years or older
  • Primary caregivers aged 18 years or older
  • Primary caregivers who can read and understand Mandarin Chinese
  • Primary caregivers who own a mobile device (e.g., smartphone or tablet) and can use the chatbot application

Who cannot take part

  • Primary caregivers who have received formal training as professional nursing assistants or caregivers
  • Primary caregivers who do not live with the patient
  • Primary caregivers who are currently or were formerly healthcare professionals (e.g., physicians, nurses, therapists)
  • Primary caregivers who do not possess a mobile device or are unable to use chatbot applications

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Pneumonia is a leading cause of death and hospitalization among the elderly in Taiwan. High-quality home care is essential to recovery and reducing readmission, yet primary caregivers often lack the specific skills needed, such as airway clearance and safe feeding techniques. Traditional education, consisting of one-time verbal instructions and paper brochures, often lacks interactivity and real-time support.

Read full original descriptionShow less

This study introduces "Pneumonia Care Helper," an interactive LINE chatbot designed to provide digital health education. The goal is to evaluate whether this digital tool is more effective than traditional paper-based education in improving the knowledge, attitudes, and caregiving practices of primary caregivers of elderly pneumonia patients. The study will compare the outcomes of caregivers using the chatbot versus those receiving standard paper-based instructions over a 5-day intervention period.

The 2 groups in the trial

  • Chatbot and Educational Videos GroupTreatment being tested

    Participants in the intervention wards will receive pneumonia health education via a dedicated chatbot. In addition to interactive text and FAQ modules, the chatbot provides four specialized educational videos covering pneumonia caregiving techniques. Caregivers can watch these videos repeatedly and access all digital materials anytime during the patient's hospitalization.

    Treatment: Chatbot with Educational Videos

  • Traditional Paper-based Education GroupExisting treatment, for comparison

    Participants in the control wards will receive traditional health education through printed brochures and standard verbal instructions from nursing staff. The content of the paper-based materials is identical to the information provided in the chatbot group, but without interactive or digital features.

    Treatment: Traditional Paper-based Education

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
14 September 2026